Cover image of PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
(3)
Science

PeerView Infectious Diseases CME/CNE/CPE Audio Podcast

Updated 3 days ago

Science
Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Read more

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

iTunes Ratings

3 Ratings
Average Ratings
3
0
0
0
0

iTunes Ratings

3 Ratings
Average Ratings
3
0
0
0
0
Cover image of PeerView Infectious Diseases CME/CNE/CPE Audio Podcast

PeerView Infectious Diseases CME/CNE/CPE Audio Podcast

Latest release on Jan 22, 2020

The Best Episodes Ranked Using User Listens

Updated by OwlTail 3 days ago

Rank #1: Roy F. Chemaly, MD, MPH, FIDSA, FACP - Managing CMV in the New Era of Antiviral Therapy: Practical Considerations in the HCT Setting

Podcast cover
Read more
Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Apr 03 2019

49mins

Play

Rank #2: David E. Griffith, MD - Exploring the Path Forward in Nontuberculous Mycobacterial Lung Disease: A MasterClass on Risk Factors, Diagnosis, and Treatment

Podcast cover
Read more
Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, health outcomes, and clinical trials, Recognize best practices in NTM-LD treatment, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Employ individualized, guideline-concordant approaches to treat patients with NTM-LD, taking into account strategies to optimize medication adherence, manage adverse events, and integrate newer therapies into clinical management.

Apr 24 2019

51mins

Play

Rank #3: Doreen Addrizzo-Harris, MD - Advances in the Management of Nontuberculous Mycobacterial Lung Disease (NTM-LD): Expert Insights From Dallas

Podcast cover
Read more
Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Jul 08 2019

28mins

Play

Rank #4: Amy Goodrich, NP - Oncology Nurse Insights Into New Agent Classes and Research in B-Cell Lymphoma: Practical Issues and Evidence for the Front-Lines of Care

Podcast cover
Read more
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.

May 15 2019

34mins

Play

Rank #5: Gregory Piazza, MD, MS - Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Podcast cover
Read more
Turning the Tide on Venous Thromboembolism: Applying Anticoagulation Best Practices to Reduce the Disease Burden

Feb 22 2019

33mins

Play